• Policy
• Regeneron enters Phase 3 in Korea
• by Lee, Hye-Kyung Nov 13, 2023 05:23am

• Policy
• Looking at the review date for GIFT No. 1 Lunsumio
• by Lee, Hye-Kyung Nov 13, 2023 05:23am

• Policy
• Korean researchers develop 1st new substance for Alzheimer's
• by Lee, Hye-Kyung Nov 9, 2023 05:43am

• Policy
• Drug pricing nego start in earnest for Tagrisso·Leclaza
• by Lee, Tak-Sun Nov 9, 2023 05:43am

• Policy
• MFDS approves P3T for talquetamab in MM patients
• by Lee, Hye-Kyung Nov 8, 2023 05:37am

• Policy
• Daewoong starts developing XR formulation of tofacitinib
• by Lee, Tak-Sun Nov 8, 2023 05:37am

• Policy
• PN injection benefit restriction suddenly halted
• by Nho, Byung Chul Nov 8, 2023 05:37am

• Policy
• A draft for reevaluation of overseas drug prices
• by Lee, Tak-Sun Nov 8, 2023 05:37am

• Policy
• Drug price reduction delayed due to suspension of execution
• by Lee, Jeong-Hwan Nov 7, 2023 05:34am

• Policy
• Lunsumio receives marketing authorization in Korea
• by Lee, Hye-Kyung Nov 6, 2023 05:27am